ORIGINAL RESEARCH article
Front. Cardiovasc. Med.
Sec. Thrombosis and Haemostasis
The impact of body composition variability on coagulation monitoring in patients on direct oral factor Xa inhibitors for treatment of venous thromboembolism
Katharina Kurzmann-Guetl 1
Deborah Raphaela Leitner 2
Thomas Gary 1
Alexander Avian 3
Andrea Beck 2
Jasmin Rabensteiner 4
Florian Prüller 4
Reinhard Bernd Raggam 1
Marianne Brodmann 1
Hermann Toplak 2
1. Medical University of Graz, Division of Angiology, Department of Internal Medicine, Graz, Austria
2. Medical University of Graz, Lipid Clinic, Division of Endocrinology and Diabetology, Department of Internal Medicine, Graz, Austria
3. Medical University of Graz, Medical Institute for Medical Informatics, Statistics and Documentation, Graz, Austria
4. Medical University of Graz, Clinical Institute of Medical and Chemical Laboratory Diagnostics, Graz, Austria
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Abstract
Background/Objectives: Evidence for the first-line treatment of venous thromboembolism (VTE) by use of direct oral anticoagulants (DOACs) is based on stratification by body-mass index (BMI) and total body weight, but does not consider body composition – defined as the distribution of fat mass (FM) and fat-free mass (FFM). Variability in body composition exists among patients with normal BMI, but is anticipated to be markedly greater in the context of overweight and obesity. Methods: The BIARIVA prospective, single-center, cross-sectional study was conducted to assess whether body composition affects blood coagulation monitoring parameters in patients on therapeutic-dose anticoagulant treatment for VTE with oral factor Xa inhibitors rivaroxaban or edoxaban. Patients were qualified for inclusion into the study if they were categorized into one of the specified BMI categories; 18 – 25, 30 – 35, or > 35 kg/m2. Body composition was determined by two bioelectrical impedance analysis (BIA) methods. The primary endpoint was the association between body composition parameters and coagulation measurements in patients treated with rivaroxaban or edoxaban, assessed by correlation analysis. Results: Thirty-six patients on rivaroxaban and 35 patients on edoxaban were finally analyzed. The main finding in this study was a significant negative correlation observed in the edoxaban group for the absolute FFM with peak plasma concentration levels (BIA method 1: r = -0.439, p = 0.008; BIA method 2: r = -0.431, p = 0.010) and with the absolute increase in plasma concentration levels from trough to peak (BIA method 1 and 2: r = -0.446, p = 0.007). No significant correlations of body composition measures with coagulation parameters were found in the rivaroxaban group. Conclusions: This study suggests that body composition might influence specific coagulation measurements in patients treated with edoxaban, but further research is required to finally determine the role of body composition in this context and to evaluate clinical implications.
Summary
Keywords
anticoagulation, Body Composition, Obesity, Oral factor Xa inhibitors, Venousthromboembolism
Received
22 December 2025
Accepted
19 February 2026
Copyright
© 2026 Kurzmann-Guetl, Leitner, Gary, Avian, Beck, Rabensteiner, Prüller, Raggam, Brodmann and Toplak. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Katharina Kurzmann-Guetl
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.